Yanis Boumber

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Neoplasms 77%
3. Small Cell Lung Carcinoma 45%
4. Methylation 42%
5. ErbB Receptors 38%
6. DNA Methylation 37%
7. Lung Neoplasms 36%
8. Epigenomics 34%
9. Protein-Tyrosine Kinases 30%
10. Immunotherapy 30%
11. Sunitinib 29%
12. CpG Islands 28%
13. Decitabine 27%
14. STA-12-8666 27%
15. Therapeutics 26%
16. Biomarkers 26%
17. Histones 24%
18. Lysine 24%
19. Histone Methyltransferases 24%
20. Genes 23%
21. Precursor Cell Lymphoblastic Leukemia-Lymphoma 22%
22. Renal Cell Carcinoma 22%
23. Neoplasm Metastasis 22%
24. mocetinostat 22%
25. pembrolizumab 21%
26. Colorectal Neoplasms 20%
27. Gene Silencing 20%
28. Histone Code 19%
29. Adenocarcinoma of Lung 19%
30. Pharmaceutical Preparations 18%
31. Cell Line 18%
32. RNA-Binding Proteins 17%
33. Proteins 17%
34. Histone Deacetylase Inhibitors 16%
35. Bile Duct Neoplasms 16%
36. Talc 16%
37. Sclerosing Solutions 16%
38. Claudins 16%
39. Erlotinib Hydrochloride 16%
40. Malignant Pleural Effusion 15%
41. Colonic Neoplasms 15%
42. Methyltransferases 15%
43. Drug Therapy 14%
44. Cell-Free Nucleic Acids 14%
45. Everolimus 14%
46. Centrosome 14%
47. Sarcopenia 14%
48. Mutation 14%
49. Circulating Neoplastic Cells 14%
50. Chromosomal Instability 14%